TVTX
Travere Therapeutics, Inc.
$54.14
+1.42%
$5.1B
No data for this timeframe.
Vol
Market Cap$5.1B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders50 funds
Inst. Value$2.0B
Inst. Activity19 buys / 13 sells
Insider Activity0B / 16S
Insider Net $-$4.9M
Reddit Sentiment67° Warm
SEC Reports15
Recent Activity
Jun 16, 2026
SEC
Travere Therapeutics disclosed the planned retirement of Chief Research Officer William Rote, effective February 17, 202
8-K — Impact 2/10
Jun 16, 2026
SEC
Two directors of Travere Therapeutics (TVTX) exercised stock options and immediately sold the resulting shares on June 1
CLUSTER — Impact 2/10
Jun 12, 2026
SEC
Director Timothy Coughlin filed a Form 144 to sell 10,000 common shares of Travere Therapeutics (TVTX), valued at approx
144 — Impact 2/10
Jun 12, 2026
Insider
Baynes Roy D. acquired via exercise 4,500 shares
Director @ $21.38 ($96.2K)
Jun 12, 2026
Insider
Baynes Roy D. sold 4,500 shares
Director @ $50.00 ($225.0K)
Jun 12, 2026
Insider
Coughlin Timothy acquired via exercise 10,000 shares
Director @ $26.52 ($265.2K)
Inst.
BANK OF AMERICA CORP — TRIM
1,345,111 shares ($40.0M)
Inst.
DRIEHAUS CAPITAL MANAGEMENT LLC — ADD
1,282,518 shares ($38.1M)
Price Targets
$57.29
+3.9% upside
Hold
Current $55.15
Low $43.00
Median $56.00
High $70.00
14 analysts
$43.00
$70.00
Analyst Ratings
8Strong Buy
11Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 18, 2026 | Evercore ISI Group | MAINTAIN | Outperform → Outperform |
| Jun 15, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Jun 12, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| Jun 3, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Jun 3, 2026 | Wedbush | REITERATE | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.32 ▼ -10.3% | $0.01 — $0.90 | 147% YoY | 8 |
| Next Q | $0.38 ▼ -30.0% | $-0.95 — $1.09 | -35% YoY | 8 |
| Current FY | $1.58 ▼ -11.9% | $-0.18 — $2.80 | 73% YoY | 8 |
| Next FY | $4.86 ▼ -3.0% | $3.24 — $7.14 | 208% YoY | 8 |
Latest Reports
NEUTRAL
8-K
2/10
Travere Therapeutics disclosed the planned retirement of Chief Research Officer William Rote, effective February 17, 202
Jun 16, 2026
NEUTRAL
CLUSTER
2/10
Two directors of Travere Therapeutics (TVTX) exercised stock options and immediately sold the resulting shares on June 1
Jun 16, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| JANUS HENDERSON GROUP PLC | $339.2M | — |
| FMR LLC | $325.9M | DOUBLED |
| BlackRock, Inc. | $231.5M | — |
| STATE STREET CORP | $147.4M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $120.2M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 12, 2026 | Baynes Roy | M | $96.2K |
| Jun 12, 2026 | Baynes Roy | SELL | $225.0K |
| Jun 12, 2026 | Coughlin Timothy | M | $265.2K |
| Jun 12, 2026 | Coughlin Timothy | SELL | $500.7K |
| May 19, 2026 | Coughlin Timothy | A | $0.00 |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
50 institutional holders with $2.0B total value (67,396,555 shares) as of 2026-Q1. Top holders: JANUS, FMR, BlackRock,. Net buying activity: 19 institutions added/increased vs 13 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 11,419,586 | $339.2M | 16.9% | — |
| 2 | FMR LLC | 10,967,967 | $325.9M | 16.3% | DOUBLED +232.3% |
| 3 | BlackRock, Inc. | 7,792,033 | $231.5M | 11.6% | — |
| 4 | STATE STREET CORP | 4,959,988 | $147.4M | 7.4% | ADD +47.8% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 4,045,812 | $120.2M | 6.0% | — |
| 6 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 3,270,513 | $97.2M | 4.9% | — |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 1,966,779 | $58.4M | 2.9% | ADD +28.2% |
| 8 | GOLDMAN SACHS GROUP INC | 1,719,721 | $51.1M | 2.6% | — |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,709,139 | $50.8M | 2.5% | — |
| 10 | TWO SIGMA INVESTMENTS, LP | 1,508,259 | $44.8M | 2.2% | — |
| 11 | BANK OF AMERICA CORP /DE/ | 1,345,111 | $40.0M | 2.0% | TRIM -27.3% |
| 12 | DRIEHAUS CAPITAL MANAGEMENT LLC | 1,282,518 | $38.1M | 1.9% | ADD +42.3% |
| 13 | WELLINGTON MANAGEMENT GROUP LLP | 1,022,272 | $30.4M | 1.5% | ADD +27.9% |
| 14 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 977,000 | $29.0M | 1.4% | TRIM -66.6% |
| 15 | Nuveen, LLC | 938,569 | $27.9M | 1.4% | — |
| 16 | DEUTSCHE BANK AG\ | 925,919 | $27.5M | 1.4% | NEW |
| 17 | D. E. Shaw & Co., Inc. | 836,544 | $24.9M | 1.2% | ADD +65.0% |
| 18 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 790,812 | $23.5M | 1.2% | — |
| 19 | RA CAPITAL MANAGEMENT, L.P. | 746,841 | $22.2M | 1.1% | NEW |
| 20 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 677,100 | $20.1M | 1.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | TRIM | 1,850,355 | 1,345,111 | -27.3% | $40.0M | 2026-Q1 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | ADD | 901,404 | 1,282,518 | +42.3% | $38.1M | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | ADD | 798,984 | 1,022,272 | +27.9% | $30.4M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TRIM | 2,927,000 | 977,000 | -66.6% | $29.0M | 2026-Q1 |
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 746,841 | — | $22.2M | 2026-Q1 |
| HSBC HOLDINGS PLC | NEW | — | 396,853 | — | $11.8M | 2026-Q1 |
| Woodline Partners LP | ADD | 164,264 | 302,666 | +84.3% | $9.0M | 2026-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 1,415,897 | 301,655 | -78.7% | $9.0M | 2026-Q1 |
| LOOMIS SAYLES & CO L P | ADD | 238,924 | 301,466 | +26.2% | $9.0M | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | ADD | 155,895 | 196,541 | +26.1% | $5.8M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | 623,390 | 176,390 | -71.7% | $5.2M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | TRIM | 219,745 | 162,235 | -26.2% | $4.8M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | DOUBLED | 58,926 | 125,879 | +113.6% | $3.7M | 2026-Q1 |
| FRANKLIN RESOURCES INC | ADD | 93,702 | 124,192 | +32.5% | $3.7M | 2026-Q1 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | NEAR_EXIT | 867,622 | 114,268 | -86.8% | $3.4M | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | DOUBLED | 39,749 | 111,633 | +180.8% | $3.3M | 2026-Q1 |
| FEDERATED HERMES, INC. | ADD | 68,299 | 92,812 | +35.9% | $2.8M | 2026-Q1 |
| MACKENZIE FINANCIAL CORP | ADD | 41,390 | 75,603 | +82.7% | $2.2M | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | TRIM | 62,186 | 33,361 | -46.4% | $991.2K | 2026-Q1 |
| Gotham Asset Management, LLC | TRIM | 55,984 | 28,377 | -49.3% | $843.1K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | ADD | 19,328 | 25,218 | +30.5% | $749.2K | 2026-Q1 |
| Marex Group plc | DOUBLED | 6,684 | 18,227 | +172.7% | $541.5K | 2026-Q1 |
| M&T BANK CORP | DOUBLED | 2,979 | 10,953 | +267.7% | $325.4K | 2026-Q1 |
| Mariner, LLC | TRIM | 18,219 | 10,847 | -40.5% | $322.2K | 2026-Q1 |
| Cerity Partners LLC | TRIM | 17,615 | 9,883 | -43.9% | $293.6K | 2026-Q1 |
15 unique insiders with 50 transactions. Net insider value: -$4.9M ($0.00 bought, $4.9M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 12, 2026 | Baynes Roy D. | Director | EXERCISE | 4,500 | $21.38 | $96.2K |
| Jun 12, 2026 | Baynes Roy D. | Director | SELL | 4,500 | $50.00 | $225.0K |
| Jun 12, 2026 | Coughlin Timothy | Director | EXERCISE | 10,000 | $26.52 | $265.2K |
| Jun 12, 2026 | Coughlin Timothy | Director | SELL | 10,000 | $50.07 | $500.7K |
| May 19, 2026 | Coughlin Timothy | Director | AWARD | 4,000 | — | — |
| May 19, 2026 | Baynes Roy D. | Director | AWARD | 4,000 | — | — |
| May 19, 2026 | Squarer Ron | Director | AWARD | 4,000 | — | — |
| May 19, 2026 | Poole Sandra | Director | AWARD | 12,000 | — | — |
| May 19, 2026 | LYONS GARY A | Director | AWARD | 4,000 | — | — |
| May 19, 2026 | LYONS GARY A | Director | AWARD | 12,000 | — | — |
| May 19, 2026 | Williams Brinkley Ruth | Director | AWARD | 4,000 | — | — |
| May 19, 2026 | Bruhn Suzanne Louise | Director | AWARD | 4,000 | — | — |
| May 19, 2026 | Coughlin Timothy | Director | AWARD | 12,000 | — | — |
| May 19, 2026 | Poole Sandra | Director | AWARD | 4,000 | — | — |
| May 19, 2026 | Bruhn Suzanne Louise | Director | AWARD | 12,000 | — | — |
| May 19, 2026 | Meckler Jeffrey A | Director | AWARD | 4,000 | — | — |
| May 19, 2026 | Baynes Roy D. | Director | AWARD | 12,000 | — | — |
| May 19, 2026 | Squarer Ron | Director | AWARD | 12,000 | — | — |
| May 19, 2026 | Meckler Jeffrey A | Director | AWARD | 12,000 | — | — |
| May 19, 2026 | Orwin John A | Director | AWARD | 12,000 | — | — |
| May 19, 2026 | Williams Brinkley Ruth | Director | AWARD | 12,000 | — | — |
| May 19, 2026 | Orwin John A | Director | AWARD | 4,000 | — | — |
| May 15, 2026 | Coughlin Timothy | Director | SELL | 3,250 | $43.49 | $141.3K |
| May 6, 2026 | Inrig Jula | CHIEF MEDICAL OFFICER | SELL | 311 | $43.95 | $13.7K |
| May 6, 2026 | ROTE WILLIAM E. | Chief Research Officer | SELL | 2,763 | $43.95 | $121.4K |
| May 6, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | SELL | 22,500 | $43.95 | $988.9K |
| May 6, 2026 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | SELL | 310 | $43.95 | $13.6K |
| May 6, 2026 | REED ELIZABETH E | Chief Legal Officer and GC | SELL | 2,076 | $43.95 | $91.2K |
| May 5, 2026 | Inrig Jula | CHIEF MEDICAL OFFICER | SELL | 2,174 | $46.65 | $101.4K |
| May 5, 2026 | Baynes Roy D. | Director | SELL | 4,500 | $46.65 | $209.9K |
| May 5, 2026 | Baynes Roy D. | Director | EXERCISE | 4,500 | $18.27 | $82.2K |
| May 5, 2026 | Heerma Peter | CHIEF COMMERCIAL OFFICER | SELL | 2,174 | $46.65 | $101.4K |
| May 5, 2026 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | SELL | 2,181 | $46.65 | $101.7K |
| May 5, 2026 | REED ELIZABETH E | Chief Legal Officer and GC | SELL | 2,174 | $46.65 | $101.4K |
| May 4, 2026 | Inrig Jula | CHIEF MEDICAL OFFICER | EXERCISE | 20,000 | $22.40 | $448.0K |
| May 4, 2026 | Inrig Jula | CHIEF MEDICAL OFFICER | SELL | 20,000 | $45.00 | $900.0K |
| May 4, 2026 | Meckler Jeffrey A | Director | EXERCISE | 8,000 | $16.33 | $130.6K |
| May 4, 2026 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | EXERCISE | 4,250 | — | — |
| May 4, 2026 | Inrig Jula | CHIEF MEDICAL OFFICER | AWARD | 8,500 | — | — |
| May 4, 2026 | Inrig Jula | CHIEF MEDICAL OFFICER | EXERCISE | 4,250 | — | — |
| May 4, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | EXERCISE | 22,500 | — | — |
| May 4, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | AWARD | 45,000 | — | — |
| May 4, 2026 | Heerma Peter | CHIEF COMMERCIAL OFFICER | EXERCISE | 4,250 | — | — |
| May 4, 2026 | Heerma Peter | CHIEF COMMERCIAL OFFICER | AWARD | 8,500 | — | — |
| May 4, 2026 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | AWARD | 8,500 | — | — |
| May 4, 2026 | Meckler Jeffrey A | Director | SELL | 8,000 | $45.00 | $360.0K |
| May 4, 2026 | REED ELIZABETH E | Chief Legal Officer and GC | EXERCISE | 20,000 | $17.96 | $359.2K |
| May 4, 2026 | REED ELIZABETH E | Chief Legal Officer and GC | AWARD | 8,500 | — | — |
| May 4, 2026 | REED ELIZABETH E | Chief Legal Officer and GC | SELL | 20,000 | $45.00 | $900.0K |
| May 4, 2026 | ROTE WILLIAM E. | Chief Research Officer | EXERCISE | 4,250 | — | — |
15 SEC filing reports analyzed. Sentiment: 3 bullish, 4 bearish, 0 mixed, 8 neutral. Avg impact: 4.5/10.
NEUTRAL
8-K
2/10
Travere Therapeutics disclosed the planned retirement of Chief Research Officer William Rote, effect
Jun 16, 2026
NEUTRAL
CLUSTER
2/10
Two directors of Travere Therapeutics (TVTX) exercised stock options and immediately sold the result
Jun 16, 2026
NEUTRAL
144
2/10
Director Timothy Coughlin filed a Form 144 to sell 10,000 common shares of Travere Therapeutics (TVT
Jun 12, 2026
BULLISH
8-K
6/10
Travere Therapeutics entered into a license and collaboration agreement with EverestMedicines for ex
Jun 2, 2026
NEUTRAL
144
2/10
Director Timothy Coughlin filed a Form 144 notice to sell 3,250 shares of Travere Therapeutics (TVTX
May 15, 2026
BEARISH
CLUSTER
6/10
Multiple Travere Therapeutics insiders, including the CEO, CFO, and CMO, sold shares in the days fol
May 7, 2026
NEUTRAL
144
2/10
Elizabeth E. Reed, an officer of Travere Therapeutics, filed a Form 144 to sell 2,174 shares for app
May 5, 2026
NEUTRAL
144
3/10
Elizabeth Reed, an officer of Travere Therapeutics, filed a Form 144 to sell 20,000 shares of common
May 4, 2026
BEARISH
CLUSTER
7/10
Five executives at Travere Therapeutics, including the CEO, CFO, and CMO, sold shares in a coordinat
Apr 23, 2026
BEARISH
CLUSTER
7/10
Four executives at Travere Therapeutics sold $2.15M in shares over two days, including significant s
Apr 16, 2026
BEARISH
CLUSTER
7/10
Travere Therapeutics insiders executed a significant cluster of open-market sales totaling $2.1 mill
Apr 16, 2026
NEUTRAL
144
3/10
Elizabeth E. Reed, an officer of Travere Therapeutics, filed a Form 144 to report a mandatory 'sell
Apr 15, 2026
BULLISH
8-K
8/10
Travere Therapeutics (TVTX) announced FDA approval of FILSPARI (sparsentan) to reduce proteinuria in
Apr 14, 2026
NEUTRAL
144
3/10
Elizabeth E. Reed, an officer of Travere Therapeutics, filed a Form 144 to notify intent to sell up
Apr 1, 2026
BULLISH
INST-CLUSTER
7/10
Four major institutions, including Fidelity, Morgan Stanley, BofA, and RenTech, significantly increa
Feb 28, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (90% buy). Based on 21 analysts: 8 strong buy, 11 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$57.29 mean target
+3.9% upside
Hold (1.27)
$43.00 Low
$70.00 High
| Metric | Value |
|---|---|
| Current Price | $55.15 |
| Target Low | $43.00 |
| Target Mean | $57.29 |
| Target Median | $56.00 |
| Target High | $70.00 |
| # Analysts | 14 |
| Recommendation | Hold (1.27) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.32 | $0.01 | $0.90 | 147.0% | -10.3% | 3↑ 2↓ | $0.2B | 40.3% | 8 |
| Next Q 2026-09-30 |
$0.38 | $-0.95 | $1.09 | -34.8% | -30.0% | 4↑ 1↓ | $0.2B | 10.0% | 8 |
| Current FY 2026-12-31 |
$1.58 | $-0.18 | $2.80 | 73.4% | -11.9% | 7↑ 1↓ | $0.7B | 42.0% | 8 |
| Next FY 2027-12-31 |
$4.86 | $3.24 | $7.14 | 207.8% | -3.0% | 4↑ 4↓ | $1.0B | 38.8% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.321 | |
| 7d ago | $0.357 | -0.036 |
| 30d ago | $0.358 | -0.037 |
| 60d ago | $0.259 | +0.062 |
| 90d ago | $0.336 | -0.015 |
10 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 18, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Jun 15, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Jun 12, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jun 3, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Jun 3, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Jun 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 6, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| May 5, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| May 5, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| May 5, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| May 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 24, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Apr 14, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Apr 14, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Apr 14, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Apr 14, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Apr 14, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 25, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Feb 6, 2026 | Piper Sandler | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 11 | 2 | 0 | 0 | 90% | |
| May 1, 2026 | 8 | 11 | 2 | 0 | 0 | 90% | |
| Apr 1, 2026 | 8 | 10 | 3 | 0 | 0 | 86% | |
| Mar 1, 2026 | 8 | 10 | 3 | 0 | 0 | 86% | |
| Feb 1, 2026 | 8 | 10 | 3 | 0 | 0 | 86% | |
| Jan 1, 2026 | 8 | 10 | 3 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 15, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 15, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Jun 15, 2026
short_volume
Short Volume: TVTX — 60.3% short (0.4M / 0.7M)
Short: 431,501 | Exempt: 18,222 | TRF Vol: 715,798 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: TVTX — 63.8% short (0.5M / 0.8M)
Short: 525,762 | Exempt: 5,721 | TRF Vol: 823,576 | Short Ratio: 63.8% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: TVTX — 66.9% short (0.4M / 0.6M)
Short: 422,005 | Exempt: 22 | TRF Vol: 630,671 | Short Ratio: 66.9% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: TVTX — 56.1% short (0.4M / 0.8M)
Short: 425,623 | Exempt: 6,875 | TRF Vol: 758,639 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: TVTX — 56.0% short (0.9M / 1.6M)
Short: 876,020 | Exempt: 18,905 | TRF Vol: 1,565,652 | Short Ratio: 56.0% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: TVTX — 68.8% short (0.5M / 0.8M)
Short: 520,771 | Exempt: 1,975 | TRF Vol: 757,063 | Short Ratio: 68.8% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: TVTX — 75.6% short (0.7M / 0.9M)
Short: 673,123 | Exempt: 1,050 | TRF Vol: 890,130 | Short Ratio: 75.6% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_volume
Short Volume: TVTX — 67.6% short (0.8M / 1.2M)
Short: 838,278 | Exempt: 30,128 | TRF Vol: 1,239,281 | Short Ratio: 67.6% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: TVTX — 76.9% short (3.7M / 4.8M)
Short: 3,676,753 | Exempt: 30,117 | TRF Vol: 4,782,357 | Short Ratio: 76.9% | Off-exchange volume (dark pool + OTC)
May 6, 2026
short_volume
Short Volume: TVTX — 56.2% short (0.5M / 0.9M)
Short: 492,474 | Exempt: 34,377 | TRF Vol: 876,591 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
May 5, 2026
short_volume
Short Volume: TVTX — 64.1% short (0.7M / 1.1M)
Short: 695,520 | Exempt: 46,804 | TRF Vol: 1,084,917 | Short Ratio: 64.1% | Off-exchange volume (dark pool + OTC)
May 4, 2026
earnings_calendar
TVTX Q1 2026 Earnings Scheduled — 2026-05-04
May 1, 2026
short_volume
Short Volume: TVTX — 63.2% short (0.4M / 0.6M)
Short: 393,786 | Exempt: 3,906 | TRF Vol: 623,042 | Short Ratio: 63.2% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
earnings_calendar
TVTX Q1 2026 Earnings Scheduled — 2026-04-30
Apr 29, 2026
earnings_calendar
TVTX Q1 2026 Earnings Scheduled — 2026-04-29
Apr 17, 2026
Clinical Trial
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
Phase Phase 3 — COMPLETED
Mar 30, 2026
Clinical Trial
Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE)
Phase Phase 2 — ACTIVE_NOT_RECRUITING